anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD) can lead to cardiac dysfunction in a condition known as cardiorenal syndrome (CRS). It is postulated that the accumulation of uremic toxins in the bloodstream, as a consequence of declining kidney function, may contribute to these adverse cardiac effects. While CRS in adults has been extensively studied, there is a significant knowledge gap with pediatric patients. Uremic toxin levels in children remain inadequately characterized and quantified compared to adults. This review aims to systematically evaluate the association between uremic toxin concentrations and cardiac changes in pediatric CRS and to examine the impact of different dialysis modalities, specifically hemodialysis and peritoneal dialysis, on uremic toxin clearance and cardiovascular parameters. To address this, we conducted a systematic literature search of PubMed, following PRISMA guidelines. We used the terms "uremic toxins" and "cardiorenal syndrome" with variations in syntax to search for studies discussing the relationship between uremic toxin levels in CKD, the subsequent impact on cardiac parameters, and the emergence of cardiac dysfunction. Full-text articles written in English, conducted on humans aged from birth to 18 years, and published until December 2021 were included. A comprehensive literature search yielded six studies, and their risk of bias was assessed using JBI Critical Appraisal Checklists. Our systematic review is registered on PROSPERO, number CRD42023460072. This synthesis intends to provide an understanding of the role of uremic toxins in pediatric CRS. The findings reveal that pediatric patients with end-stage CKD on dialysis exhibit elevated uremic toxin levels, which are significantly associated with cardiovascular disease parameters. Additionally, the severity of CKD correlated with higher uremic toxin levels. No conclusive evidence was found to support the superiority of either hemodialysis or peritoneal dialysis in terms of uremic toxin clearance or cardiovascular outcomes. More pediatric-specific standardized and longitudinal studies are needed to develop targeted treatments and improve clinical outcomes and the quality of life for affected children.
OBJECTIVES: Refractory functional constipation is a challenging condition to manage in children. The use of transanal irrigation (TAI) is well reported in children with neurological disorders as well as anorectal malformations but less so in children with functional disorders of defecation. The objective of our study was to evaluate the effectiveness, safety and outcomes of TAI in children with functional constipation.
METHODS: PubMed, Scopus and Google Scholar were searched for publications related to the use of TAI in functional constipation. Data regarding the study design, sample size, patient characteristics, investigator-reported response to TAI and adverse effects were extracted from studies that met the selection criteria. The inverse variance heterogeneity model was used for ascertaining the summary effect in this meta-analysis.
RESULTS: The search strategy yielded 279 articles of which five studies were included in the final review. The studies were from the United Kingdom (n = 2), Netherlands (n = 2) and Denmark (n = 1). These studies included 192 children with a median age ranging from 7 to 12.2 years old. The TAI systems used in these studies were: Peristeen (n = 2), Peristeen or Qufora (n = 1), Alterna (n = 1) and Navina (n = 1). The follow-up duration ranged from 5.5 months to 3 years. Eleven (5.7%) children did not tolerate TAI and withdrew from treatment soon after initiation. The pooled investigator-reported success of TAI was 62% (95% CI: 52%-71%). The most common adverse event was pain which was experienced by 21.7% of children. A total of 27 (14%) were successfully weaned off TAI at the last follow-up.
CONCLUSIONS: TAI is reported to be successful in 62% of children with refractory functional constipation. There is a need for well-designed prospective trials to evaluate this treatment option in children with refractory functional constipation.
Patients in this group continued their routine medical treatment program without any treatment. Moreover, ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes.
The "Anatase" Spine Surgery Navigation System, is composed of an Optical Tracker, Computer, No-Touch Reader and Dynamic Reference Frame (DRF). The Optical Tracker is a position sensor, it tracks the position of instruments with DRF by infrared light, allowing the instrument and vertebra to be positioned. The Computer is a touch screen panel PC running the proprietary spine NAVI software that guides the surgical procedure and display the results of the operation and computation. A No-Touch Reader, which attached on the Optical Tracker, is a no-touch sensor to identify instruments. It's a unique design and identification technology allows the instrument to be wirelessly identified, reducing the risk and time required to set up the instrument type. The system can track the position of patient's vertebra and instruments by mounting the DRF on patient's vertebra and instruments.

The "Anatase" Spine Surgery Navigation System is indicated for precise positioning of surgical instruments or spinal implants during general spinal surgery. The system helps to guide surgeons with real-time image and provides preoperative planning and intraoperative control.
The current invention comprises compositions and methods for protecting a neuronal cell of a subject from a toxic insult. The method includes delivering an effective amount of a neuroprotective compound to the neuronal cells before or after the toxic insult. The neuroprotective compounds contain a peroxisome proliferator activated receptor (“PPAR-γ”) binding moiety with either a phenolic ring moiety or a prostaglandin (“PG”) with a reactive α,β-unsaturated carbonyl group on the cyclopentenone ring. Other novel compounds are also disclosed. The toxic insult that impinges upon the neuronal cell may be an acute process, or chronic disease process. Oxidative stress (e.g. hydrogen peroxide, and glutamate), injury, and secondary physiological responses to injury are among the acute processes discussed. Clinical disease processes that comprise oxidative stress, inflammatory responses, strokes, Alzheimer's disease, dementia, and Parkinson's disease are also addressed. Because PPAR-γ agonists are used to treat type II diabetes, a condition that leads to neurological complications, a single agent that can target both conditions is of great therapeutic value.
The invention discloses an anti-MUC1 monoclonal antibody as well as light chain and heavy chain variable regions thereof. Light chain and heavy chain variable regions of the anti-MUC1 monoclonal antibody FMU-MUC1-No.1 having a bioactivity are provided, an amino acid sequence of the light chain variable region is shown in SEQ ID NO. 1 and an amino acid sequence of the heavy chain variable region is shown in SEQ ID NO. 2. A group of mouse anti-MUC1 mAbs are prepared through a genetic engineering technology and a hybridoma technology; a hybridoma cell line capable of stably excreting high-specificity anti-MUC1 mAb is screened; ascites is prepared to obtain high-specificity and high-affinity anti-MUC1 mAb FMU-MUC1-No. 1. Uniquenesses and CDR sequences of a sequence of a gene sequence and a corresponding protein sequence are confirmed; the monoclonal antibody provides support for research and development of anti-MUC1 chimeric or humanized genetic engineering antibodies or molecular diagnosis and treatment reagents.
PURPOSE: Most cytotoxic drugs are dosed using body surface area (BSA), yet not all cancer patients receive the full BSA-determined dose. Prior work suggests that breast cancer patients who are obese are more likely to experience dose reduction than normal weight patients. However, the factors driving dose reduction remain unclear.
METHODS: In 452 women diagnosed with stage I-IIIA primary breast cancer at Kaiser Permanente Northern California, we evaluated the association between obesity and dose reduction, and further explored other factors in relation to dose reduction, including various sociodemographic characteristics, tumor characteristics, and comorbidities. Study participants were a part of the Pathways Study, diagnosed between 2006 and 2013 and treated with cyclophosphamide + doxorubicin, followed by paclitaxel (ACT). Dose reduction was assessed using first cycle dose proportion (FCDP) and average relative dose intensity (ARDI), a metric of dose intensity over the course of chemotherapy.
RESULTS: Overall, 8% of participants received a FCDP < 90% and 21.2% had an ARDI < 90%, with dose reduction increasing with body mass index. In adjusted logistic regression models, obese women had 4.1-fold higher odds of receiving an ARDI < 90% than normal weight women (95% CI: 1.9-8.9; p-trend = 0.0006). Increasing age was positively associated with an ADRI < 90%, as was the presence of comorbidity. Dose reduction was less common in later calendar years.
CONCLUSION: Results offer insight on factors associated with chemotherapy dosing for a common breast cancer regimen. Larger studies are required to evaluate relevance to other regimens, and further work will be needed to determine whether dose reductions impact outcomes in obese women.
Chicago Family Health Center clinics are randomly assigned to any of the 5 steps. The PORTAL-PTSD intervention is implemented after clinic staff and clinicians have been trained.
I-Fiber Pearl 200g, with inulin fiber. Eat 200g for once, and once a day.
FIELD: veterinary immunology. SUBSTANCE: the suggested method deals with injecting glycopin as 0.2%-solution at the dosage of 1.5-2.0 ml 12-18 h before immunization with polyvalent vaccine and twice at 24-h-long interval after immunization. The method enables to increase prophylactic efficiency of vaccination at the background of natural virus-bearing. This method could be applied for preventing sickness with mixed viral infections in calves. EFFECT: higher efficiency of prophylaxis. 4 ex, 4 tbl
ENSAND seeks to increase the frequency of egg consumption among students in classes 1-3 in public primary schools and their younger siblings aged 6-59 months in local government areas (LGAs) with a high proportion of bottom of the pyramid (BoP) households. GAIN's intervention is two-pronged in Kaduna State. One component will involve improving the egg value chain supplying the Home-Grown School Feeding Program (HGSFP) for primary school children and the other will involve using a social marketing approach to increase parents' willingness to purchase and feed eggs to their young children aged 6-59 months. In Federal Capital Territory (FCT) and Kebbi States, GAIN's intervention will focus only on supplying eggs to primary school children.

This evaluation of the ENSAND program will use a parallel group mixed-methods quasi-experimental before-after design to assess the effectiveness of the intervention on children's frequency of egg consumption in Kaduna (intervention) and Kano (control) States. The evaluation will be carried out in 3 intervention and 3 control LGAs, with clustering at the level of the school. Data will be collected through household surveys with caregivers and school-aged children (N=1,332 at baseline and endline), egg value chain actor key informant interviews (KIIs, N=3) and semi-structured interviews (N=191) at baseline, midline, and endline, and focus group discussions (FGDs, N=9 FGDs at midline and endline) with caregivers of young children. Households with school- and pre-school aged children will be identified through the sampled public primary schools, and caregivers and school-aged children will be interviewed at baseline and endline in intervention and control LGAs. The same schools will be used at both times points but cross-sectional samples will be drawn at baseline and endline. Egg value chain actors will be identified in the intervention LGAs in Kaduna to participate in KIIs and semi-structured interviews at baseline, midline, and endline to assess changes in the functioning of the value chain over time. FGDs with caregivers of young children will be conducted at midline and endline. The qualitative findings will be used to understand experiences with the interventions and findings will be triangulated with results from the household and egg value chain interviews.

In FCT and Kebbi, the evaluation will be limited to KIIs (N=4) and semi-structured interviews (N=102) with egg value chain actors at baseline, midline, and endline. The findings will be used to validate and triangulate with the monitoring data GAIN will be collecting from value chain actors.
As people age, the risk and progression of colorectal cancer (CRC), along with cholesterol levels, tend to increase. Nevertheless, epidemiological studies on serum lipids and CRC have produced conflicting results. We previously demonstrated that the reduction of squalene epoxidase (SQLE) due to accumulated cholesterol within cells accelerates CRC progression through the activation of the β-catenin pathway. This study aimed to investigate the mechanism by which age-related cholesterol accumulation within tissue accelerates CRC progression and to assess the clinical significance of SQLE in older individuals with elevated CRC risk. Using machine learning-based digital image analysis with fluorescence-immunohistochemistry, we assessed SQLE, GSK3βpS9 (GSK3β activity inhibition through serine 9 phosphorylation at GSK3β), p53 wild-type (p53WT), and p53 mutant (p53MT) levels in CRC tissues. Our analysis revealed a significant reduction in SQLE, p53WT, and p53MT and increase in GSK3βpS9 levels, all associated with the substantial accumulation of intra-tissue cholesterol in aged CRCs. Cox analysis underscored the significant influence of SQLE on overall survival and progression-free survival in grade 2-3 CRC patients aged over 50. SQLE and GSK3βpS9 consistently exhibited outstanding prognostic and diagnostic performance, particularly in older individuals. Furthermore, combining SQLE with p53WT, p53MT, and GSK3βpS9 demonstrated a robust diagnostic ability in the older population. In conclusion, we have identified that individuals aged over 50 face an increased risk of CRC progression due to aging-linked cholesterol accumulation within tissue and the subsequent reduction in SQLE levels. This study also provides valuable biomarkers, including SQLE and GSK3βpS9, for older patients at elevated risk of CRC.
In the US, end-of-life health care (EOLHC) is often intensive and invasive, and at times may involve care that is inconsistent with patient values. US Muslims may not receive appropriate religious support, experience uncertainty around end-of-life decision-making, and under-utilize palliative and hospice care. As technological advancements and treatment options rise in EOLHC, Muslim American patients and their families need to understand more about the treatment options that are consistent with their beliefs. The objective of this study was to determine the efficacy of a pilot mosque-based educational workshop focused on increasing Muslim Americans' religious bioethics knowledge about end-of-life healthcare. Intervention sites were four mosques with racially and ethnically diverse members, two in the Chicago metropolitan area and two in the Washington, D.C. area. Eligible participants were self-reported Muslims, aged 18 years or older, who were proficient in English. The intervention included a pre and post-test survey and a workshop focused on the Islamic bioethical perspectives on EOLHC. Knowledge was measured with six true-false questions. Baseline and post-intervention scores were analyzed by McNemar's test and bivariate correlation. Overall, the analysis showed a significant improvement in post-intervention participant knowledge. There was increased knowledge of Islamic bioethical views on the moral status of seeking healthcare, brain death controversies, and religious perspectives on withholding or withdrawing life support near the end of life. Our pilot intervention successfully increased participant knowledge and underscores the need to improve the Muslim community's knowledge about the bioethical dimensions of EOLHC.
PURPOSE:To provide a safe cosmetic having stable whitening activity, antiinflammatory activity and water-retainability by compounding the water-soluble extract of the fruit of Lagenaria leucantha Rusby ver. ciauat Makino. CONSTITUTION:A cosmetic contains the water-soluble extract of the fruit of Lagenaria leucantha Rusby ver. ciauat Makino. For example, the fruit may be extracted with one or a mixture of solvents comprising alcohols such as water, methanol, ethanol and 1,3-butylene glycol, acetone, etc., by a heating extraction method or an ordinary temperature extraction method. The extract is compounded in a solid amount of 0.01-10wt.%, preferably 0.1-5.0wt.%, based on the total amount of the cosmetic.
General: Because azithromycin is principally eliminated via the liver, caution should be exercised when azithromycin is administered to patients with impaired hepatic function. Due to the limited data in subjects with GFR <10 mL/min, caution should be exercised when prescribing azithromycin in these patients. (See CLINICAL PHARMACOLOGY - Special Populations - Renal Insufficiency.)

Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarization.

Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.

Prescribing azithromycin tablet in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Severe airway inflammatory disorders impose a significant societal burden, and the available treatments are unsatisfactory. High levels of neutrophil extracellular trap (NET) and cell-free DNA (cfDNA) were detected in the inflammatory microenvironment of these diseases, which are closely associated with persistent uncontrolled neutrophilic inflammation. Although DNase has proven to be effective in mitigating neutrophilic airway inflammation in mice by reducing cfDNA and NET levels, its clinical use is hindered by severe side effects. Here, we synthesized polyglycerol-amine (PGA) with a series of hydroxyl/amine ratios and covered them with black phosphorus (BP) nanosheets. The BP nanosheets functionalized with polyglycerol-50% amine (BP-PGA50) efficiently lowered cfDNA levels, suppressed toll-like receptor 9 (TLR9) activation and inhibited NET formation in vitro. Importantly, BP-PGA50 nanosheets demonstrated substantial accumulation in inflamed airway tissues, excellent biocompatibility, and potent inflammation modulation ability in model mice. The 2D sheet-like structure of BP-PGA50 was identified as a crucial factor for the therapeutic efficacy, and the hydroxyl/amine ratio was revealed as a significant parameter to regulate the protein resistance, cfDNA-binding efficacy, and cytotoxicity. This study shows the promise of the BP-PGA50 nanosheet for tackling uncontrolled airway inflammation, which is also significant for the treatment of other neutrophilic inflammatory diseases. In addition, our work also highlights the importance of proper surface functionalization, such as hydroxyl/amine ratio, in therapeutic nanoplatform construction for inflammation modulation.
PCT No. PCT/FR97/01163 Sec. 371 Date Jun. 9, 1998 Sec. 102(e) Date Jun. 9, 1998 PCT Filed Jun. 30, 1997 PCT Pub. No. WO98/03148 PCT Pub. Date Jan. 29, 1998Pressurised cosmetic compositions provided in pressurised form in an aerosol device in the presence of a propellant, and capable of forming a foam, are disclosed. Said compositions comprise a cosmetically acceptable medium containing at least one binding polymer, at least one oxyalkylene silicone and at least 30 wt % of a water-soluble solvent having a boiling point lower than 85 DEG  C. Foams produced by the expansion in air of said cosmetic compositions are also disclosed. Furthermore, a method for cosmetically treating keratin fibres such as hair, wherein a foam produced by the expansion in air of said cosmetic composition is applied to said keratin fibres, is disclosed.
Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
An efficient smoking quitting tea is disclosed. The smoking quitting tea is prepared from 15-20 parts by weight of green tea, 13-15 parts by weight of broadleaf holly leaves, 7-13 parts by weight of grosvenor momordica fruit, 7-10 parts by weight of kudzu vine root, 5-8 parts by weight of mint, 4-7 parts by weight of liriope spicata, 1-3 parts by weight of fragrant solomonseal rhizome, 4-7 parts by weight of loquat leaves, 3-5 parts by weight of Chinese bellflower and 2-4 parts by weight of chrysanthemum flower. A preparing method of the efficient smoking quitting tea is also disclosed. Components in the smoking quitting tea have effects of inhibiting a carving for tobacco. Tea soup contains a plurality of vitamins and a large amount of tea polyphenols, and can expel body toxins caused by smoking out of the body. In addition, the tea soup can excite a person, can replace excitement brought by nicotine and can inhibit the carving for tobacco for a smoker. The added grosvenor momordica fruit and the kudzu vine root can clear and moisten throats, and the fragrant solomonseal rhizome can nourish yin and moisten the lung, and therefore the smoking quitting tea has a function of effectively protecting the lung of a smoker.
A proxy data augmentation system and method intelligently augments digital information sets with proxy data using analytical processing technology. The proxy data system and method identifies fields in a digital information set that are candidates for modification using proxy data. After identifying a candidate field, an analytical process is invoked to evaluate a context of the candidate field. In one embodiment, once the context and at least one other parameter associated with the digital information set are evaluated, the proxy data augmentation system and method can determine appropriate proxy data to populate the candidate field and modify the digital information set with the determined proxy data. The modified document can then be sent to a recipient data processing system. Additionally, the digital information set submitting and/or recipient data processing system can be notified of the existence and identification of the proxy data.
PROBLEM TO BE SOLVED: To obtain the subject composition low in irritativeness and excellent in an effect for removing Staphylococcus aureus by using an N-acylglutamic acid salt as an active ingredient. SOLUTION: This detergent composition contains an N-acylglutamic acid salt as an active ingredient. The N-acylglutamic acid salt can be represented by the formula (R is a 7-17C alkyl, an alkeny1; M1 , M2 are each H, an alkali metal, amino). The sodium, potassium and monoethanolamine salts of N- Lauroylglutamic acid and N-coconut oil acylglutamic acid are preferable among the compounds of the formula. The detergent composition preferably contains the above active ingredient in an amount of 20-40 wt.%. One or more surfactants generally used for detergents may simultaneously be used in a range not deteriorating the effect. For example, one or more additives such as an anti- inflammatory agent and a moisturizing agent may further be compounded.